Interplay of Liver–Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy

Csaba Matyas, Katalin Erdelyi, Eszter Trojnar, Suxian Zhao, Zoltan V. Varga, Janos Paloczi, Partha Mukhopadhyay, Balazs T. Nemeth, György Haskó, Resat Cinar, Robim M. Rodrigues, Yeni Ait Ahmed, Bin Gao, Pal Pacher – 30 August 2019

Management of Patients With Erythropoietic Protoporphyria–Related Progressive Liver Disease

Zaid S. Ardalan, Sujievvan Chandran, Abhinav Vasudevan, Peter W. Angus, Andrew Grigg, Simon He, Graeme A. Macdonald, Simone I. Strasser, Courtney J. Tate, Glen A. Kennedy, Adam G. Testro, Paul J. Gow – 30 August 2019 – Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction of protoporphyrin IX (PPIX), which can lead to progressive liver disease characterized by recurrent EPP crises and end‐stage liver disease.

CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis–Driven Hepatocarcinogenesis via ERK‐Dependent PKM2 Nuclear Relocalization and Activation

Tin‐Lok Wong, Kai‐Yu Ng, Kel Vin Tan, Lok‐Hei Chan, Lei Zhou, Noélia Che, Ruby L.C. Hoo, Terence K. Lee, Stéphane Richard, Chung‐Mau Lo, Kwan Man, Pek‐Lan Khong, Stephanie Ma – 30 August 2019

Subscribe to